Jenny Y. Chien

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

Gregory Gaich, Jenny Y. Chien, Haoda Fu et al. · Cell Metabolism · 2013 · 879 citations · Full text

Medicine, Endocrinology, Pharmacology +11

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance

Barbara J. Ring, Jenny Y. Chien, Kimberly K. Adkison et al. · Journal of Pharmaceutical Sciences · 2011 · 201 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

Patrick Poulin, Rhys D.O. Jones, Hannah M. Jones et al. · Journal of Pharmaceutical Sciences · 2011 · 171 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution

Rhys D.O. Jones, Hannah M. Jones, Malcolm Rowland et al. · Journal of Pharmaceutical Sciences · 2011 · 135 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes

Peggy L. Barrington, Jenny Y. Chien, H. D. Hollis Showalter et al. · Diabetes Obesity and Metabolism · 2011 · 120 citations

Medicine, Pharmacokinetics, Pharmacology +17